Conditions: Asthma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 806
Healthy volunteers: no

Brief summary:
This multicenter, prospective study will evaluate the baseline participant characteristics (including biomarkers) associated with a variety of individual and composite clinical outcomes in participants with moderate to severe asthma initiating treatment with omalizumab.

Detailed description:

Arms:
arm 1: Participants with allergic asthma, who have decided to initiate treatment with omalizumab will be observed until a maximum follow-up of 12 months, death, withdrawal of consent, loss to follow-up, or study closure, whichever occurs first.

Interventions: intervention 1: Omalizumab
Intervention descriptions: intervention 1: Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.

Protocol document: